<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01504503</url>
  </required_header>
  <id_info>
    <org_study_id>645/09</org_study_id>
    <nct_id>NCT01504503</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study for Donepezil Hydrochloride 10 mg Tablets Under Fasting Condition</brief_title>
  <official_title>Open Label, Balanced, Randomized, Two-treatment, Two-period, Two Sequence, Single Dose, Crossover, Oral Bioequivalence Study of Donepezil Hydrochloride Tablets 10mg With ARICEPT® (Containing Donepezil Hydrochloride) Tablets 10 mg in Healthy, Adult, Human Subjects Under Fasting Condition.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, balanced, randomized, two-treatment, two-period, two sequence, single
      dose, crossover, oral bioequivalence study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was an open label, balanced, randomized, two-treatment, two-period, two
      sequence,single dose, crossover, oral bioequivalence study of Donepezil Hydrochloride tablets
      10 mg of Dr. Reddy's Laboratories Limited, India comparing with that of ARICEPT® (containing
      Donepezil Hydrochloride) tablets 10 mg of Pfizer Inc, New York, 10017 in healthy, adult,
      human subjects under fasting condition. 28 subjects are enrolled in the study, and 26
      subjects are completed the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area unde curve (AUC)</measure>
    <time_frame>Pre-dose 0.5,0.75,1,1.5,2,2.5,3,3.5,4,4.5,5,5.5,6,7,8,9,10,12,16,24,36,48,72,96,120,144,168,192,216,240 and 264 hours post-dose</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Donepezil Hydrochloride10 mg Tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Donepezil Hydrochloride 10 mg Tablets of Dr. Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aricept 10 mg Tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aricept 10 mgTablets of Pfizer Inc</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil Hydrochloride</intervention_name>
    <description>Donepezil Hydrochloride Tablets 10 mg</description>
    <arm_group_label>Donepezil Hydrochloride10 mg Tablets</arm_group_label>
    <other_name>Aricept 10 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aricept</intervention_name>
    <description>Aricept 10 mg Tablets</description>
    <arm_group_label>Aricept 10 mg Tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide written informed consent.

          -  Must be healthy, adult, human beings within 18 and 45 years of age (both inclusive)
             weighing at least 50 kg.

          -  Having a body mass index between 18.0 and 24.9 (both inclusive), calculated as weight
             in Kg/height in m2.

          -  Must be of normal health as determined by medical history, physical examination and
             laboratory investigation performed within 28 days prior to the commencement of the
             study. (Laboratory values must be within normal limits or considered by the physician
             / investigator to be of no clinical significance).

          -  Female Subjects

               -  Of child bearing potential practicing an acceptable method of birth control for
                  the duration of the study as judged by the investigator(s), such as condoms,
                  foams, jellies, diaphragm, intrauterine device (IUD), or abstinence.

               -  Surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or
                  hysterectomy has been performed on the subject)

        Exclusion Criteria:

          -  Incapable of understanding the informed consent.

          -  Systolic blood pressure less than 90 mm of Hg 140 mm of Hg.

          -  Diastolic blood pressure less than 60 mm of Hg 90 mm of Hg.

          -  Oral temperature is below 95.0°F or above 98.6°F.

          -  Pulse rate below 50/min or above 100/min.

          -  History of hypersensitivity or idiosyncratic reaction to investigational drug product
             or any other related drugs.

          -  Any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal
             function.

          -  Consumption of grapefruit for the past ten days prior to the check-in, in each period.

          -  Regular smoker who has a habit of smoking more than nine cigarettes per day and has
             difficulty in abstaining from smoking during sample collection period.

          -  Habit of alcoholism and difficulty in abstaining from alcohol during the sample
             collection period.

          -  Difficulty in abstaining from xanthene containing food or beverages (like tea, coffee,
             chocolates and cola drinks) during the sample collection period.

          -  Intake of over the counter (OTC) or prescribed medications and enzyme modifying
             medication or systemic medication for the last 30 days before dosing.

          -  Clinically significant abnormalities and / or with significant diseases.

          -  Confirmed positive in alcohol screening.

          -  Confirmed positive in selected drug of abuse.

          -  Participated in any other clinical investigation using experimental drug/donated blood
             in past 90 days before the date of start of study.

          -  Confirmed positive in urine pregnancy test.

          -  Female detected to be pregnant, breast feeding or who is likely to become pregnant
             during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. L Krishna Murthy</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bioserve Clinical Research Private Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bioserve Clinical Research Private Limited</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500 037</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2012</study_first_submitted>
  <study_first_submitted_qc>January 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2012</study_first_posted>
  <last_update_submitted>January 5, 2012</last_update_submitted>
  <last_update_submitted_qc>January 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Donepezil</keyword>
  <keyword>crossover</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

